Dehydroepiandrosterone

Suppliers

Names

[ CAS No. ]:
53-43-0

[ Name ]:
Dehydroepiandrosterone

[Synonym ]:
3β-Hydroxy-androst-5-ene-17-one
DHEA
17-Hormoforin
3-β-hydroxyandrost-5-en-17-one
3b-hydroxy-Androst-5-en-17-one
(3b)-3-Hydroxyandrost-5-en-17-one
3β-hydroxy-androst-5-en-17-one
(3β)-3-hydroxy-Androst-5-en-17-one
D5-Androsten-3b-ol-17-one
(3β)-3-Hydroxyandrost-5-en-17-one
MFCD00003613
Psicosterone
Prasterone
trans-Dehydroandrosterone
3b-Hydroxyandrost-5-ene-17-one
Androst-5-en-17-one, 3β-hydroxy-
Androst-5-en-17-one, 3-hydroxy-, (3β)-
3b-Hydroxyandrost-5-en-17-one
Prestara
3β-Hydroxy-5-androsten-17-one
Intrarosa
Deandros
dehydroisoandrosterone
(3β)-3-Hydroxyandrost-5-ene-17-one
Androst-5-ene-3b-ol-17-one
Androst-5-ene-3β-ol-17-one
5-Androsten-3β-ol-17-one
Dehydro-epi-androsterone
17-Chetovis
Dehydroepiandrosterone
didehydroepiandrosterone
3β-Hydroxyandrost-5-ene-17-one
D5-Androsten-3β-ol-17-one
Diandrone
EINECS 200-175-5
Astenile
3β-Hydroxyandrost-5-en-17-one
UNII-459AG36T1B
Diandron

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
426.7±45.0 °C at 760 mmHg

[ Melting Point ]:
146-151ºC

[ Molecular Formula ]:
C19H28O2

[ Molecular Weight ]:
288.424

[ Flash Point ]:
182.1±21.3 °C

[ Exact Mass ]:
288.208923

[ PSA ]:
37.30000

[ LogP ]:
3.42

[ Vapour Pressure ]:
0.0±2.3 mmHg at 25°C

[ Index of Refraction ]:
1.560

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
BV8396000
CHEMICAL NAME :
Androst-5-en-17-one, 3-beta-hydroxy-
CAS REGISTRY NUMBER :
53-43-0
BEILSTEIN REFERENCE NO. :
2058110
LAST UPDATED :
199707
DATA ITEMS CITED :
18
MOLECULAR FORMULA :
C19-H28-O2
MOLECULAR WEIGHT :
288.47
WISWESSER LINE NOTATION :
L E5 B666 FV LUTJ A1 E1 OQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
900 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
159 gm/kg/84W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
25 gm/kg/52D-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Reproductive - Tumorigenic effects - ovarian tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
400 mg/kg/50D-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Reproductive - Tumorigenic effects - ovarian tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1800 mg/kg
SEX/DURATION :
female 2-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 15-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
357 mg/kg
SEX/DURATION :
male 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
600 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Endocrine - changes in luteinizing hormone Endocrine - estrogenic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
240 mg/kg
SEX/DURATION :
female 13-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
240 mg/kg
SEX/DURATION :
female 13-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
TYPE OF TEST :
Unscheduled DNA synthesis

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
3780 mg/kg/14D (Continuous)
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 52,2977,1992 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 81794 No. of Facilities: 28 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 700 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 81794 No. of Facilities: 39 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 2085 (estimated) No. of Female Employees: 1457 (estimated)

Safety Information

[ Symbol ]:

GHS02, GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H225-H301 + H311 + H331-H370

[ Precautionary Statements ]:
P210-P260-P280-P301 + P310-P311

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S24/25

[ RIDADR ]:
UN1230 - class 3 - PG 2 - Methanol, solution

[ WGK Germany ]:
2

[ RTECS ]:
BV8396000

[ HS Code ]:
2937290090

Synthetic Route

Precursor & DownStream

Precursor

  • Dehydroepiandrosterone acetate
  • (17Ξ)-spiro[androst-5-en-17,2'-[1,3]oxathiolan]-3β-ol
  • (20E)-3beta-Hydroxypregna-5,16-dien-20-one 20-oxime 3-acetate
  • 3β-[2-(triphenylsilyl)ethoxycarbonyloxy]androst-5-en-17-one
  • 3beta-(Methoxymethoxy)androst-5-en-17-one
  • Pregnenolone
  • 6β-acetoxy-3α,5α-cyclo-androstanone-(17)
  • 5-androsten-3β,17α-diol-17-carboxylic acid

DownStream

  • (1R,3S,5E)-5-[(2E)-2-[(3aS,7aS)-1-(4-hydroxy-4-methylpentoxy)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
  • (16α-bromine)-3α-Dehydroepiandrosterone
  • 5a-androstane
  • 17-Iodoandrosta-5,16-dien-3beta-ol
  • 4-(2,5-DIMETHYL-1H-PYRROL-1-YL)-2-HYDROXYBENZOIC ACID
  • 19-Hydroxy-4-androsten-3,17-dione
  • (10R,13S)-17-Chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
  • 10a,12a-dimethyl-2,3,3a,3b,4,5,8,9,10,10b,11,12-dodecahydroindeno[4,5-i][3]benzazepine-1,7-dione
  • Testosterone
  • Androstenedione

Customs

[ HS Code ]: 2937290014

[ Summary ]:
HS:2937290014 (3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17(2h)-one VAT:17.0% Tax rebate rate:9.0% Supervision conditions:l MFN tariff:4.0% General tariff:30.0%

Articles

Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.

Biochem. Pharmacol. 90(3) , 288-96, (2014)

Inhibition of 17α-hydroxylase/17,20-lyase (CYP17), which dictates the proceeding of androgen biosynthesis, is recommended as an effective treatment for androgen-dependent diseases. However, androgen d...

Mechanistic Scrutiny Identifies a Kinetic Role for Cytochrome b5 Regulation of Human Cytochrome P450c17 (CYP17A1, P450 17A1).

PLoS ONE 10 , e0141252, (2015)

Cytochrome P450c17 (P450 17A1, CYP17A1) is a critical enzyme in the synthesis of androgens and is now a target enzyme for the treatment of prostate cancer. Cytochrome P450c17 can exhibit either one or...

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...


More Articles


Related Compounds

  • dehydroepiandrosterone
  • dehydroepiandrosterone
  • Dehydroepiandrosterone-d5
  • Dehydroepiandrosterone-13C3
  • Dehydroepiandrosteroneacetate
  • 7-Keto-dehydroepiandrosterone
  • 4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
  • 1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
  • 2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
  • 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
  • (4-Methyl-tetrahydro-furan-2-yl)-methanol
  • N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
  • 4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
  • tert-Butyl-DL-alanine
  • 1-methyl-N-(2-(6-oxopyridazin-1(6H)-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide
  • 4-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-ethylbenzenesulfonamide